A phase II, randomized, double-blind, placebo-controlled, parallel-group study of daclizumab in patients With chronic, persistent asthma

Trial Profile

A phase II, randomized, double-blind, placebo-controlled, parallel-group study of daclizumab in patients With chronic, persistent asthma

Completed
Phase of Trial: Phase II

Latest Information Update: 15 Nov 2008

At a glance

  • Drugs Daclizumab (Primary)
  • Indications Asthma
  • Focus Therapeutic Use
  • Sponsors PDL BioPharma
  • Most Recent Events

    • 15 Nov 2008 Primary endpoint 'Forced expiratory volume in 1 second' has been met.
    • 10 Sep 2007 Status changed from in progress to completed.
    • 27 Mar 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top